Litcius/Paper detail

nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial

Peter Oppelt, Jessica Ley, Mackenzie Daly, Jason T. Rich, Randal C. Paniello, Ryan S. Jackson, Patrik Pipkorn, Jingxia Liu, Hiram A. Gay, Kevin Palka, Prakash Neupane, Steven Powell, William C. Spanos, Mark M. Gitau, José P. Zevallos, Wade L. Thorstad, Douglas R. Adkins

2021Medical Oncology16 citationsDOI

Topics & Concepts

PaclitaxelCetuximabMedicineCisplatinOncologyChemoradiotherapyInternal medicineHead and neck squamous-cell carcinomaChemotherapyClinical endpointInduction chemotherapyRadiation therapyHead and neck cancerUrologyCancerRandomized controlled trialColorectal cancerHead and Neck Cancer StudiesHead and Neck Surgical OncologySalivary Gland Tumors Diagnosis and Treatment
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial | Litcius